奥泰生物: 上海礼丰律师事务所关于杭州奥泰生物技术股份有限公司2024 年限制性股票激励计划授予价格调整及预留授予事项之法律意见书

Core Viewpoint - The legal opinion letter from Shanghai Lifeng Law Firm confirms that Hangzhou Aotai Biotechnology Co., Ltd. has complied with relevant laws and regulations regarding the adjustment of the grant price and the reserved grant of the 2024 restricted stock incentive plan [1][4][13] Group 1: Approval and Authorization - The board of directors approved the adjustment of the grant price from 29.2400 yuan/share to 26.2993 yuan/share for the incentive plan [6][8] - The supervisory board confirmed that the adjustment process was legal and compliant with regulations, and the reserved grant date was set for August 29, 2025, for 188,000 shares to 41 eligible recipients [6][9] Group 2: Specifics of the Adjustment - The company plans to distribute cash dividends of 1.50 yuan per share, totaling 116,802,501 yuan, based on a total share capital of 79,280,855 shares [8] - The adjustment of the grant price was approved during meetings held on August 29, 2025, and the new price reflects compliance with the management regulations [7][9] Group 3: Grant Conditions and Recipients - The grant conditions have been met, and the recipients of the reserved stock are in accordance with the relevant laws and regulations [11][13] - The board confirmed that the grant date and recipients comply with the management regulations and the incentive plan [9][12]